Statistical and Epidemiological Study Based on the Use of Convalescent Plasma for the Management of Patients With COVID-19 (PROMETEO)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04452812 |
Recruitment Status : Unknown
Verified June 2020 by Universidad Autonoma de Coahuila.
Recruitment status was: Not yet recruiting
First Posted : June 30, 2020
Last Update Posted : July 7, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
The health contingency established against the Severe Acute Respiratory Syndrome associated type 2 Coronavirus (SARS-CoV-2) has promoted a race against the clock for the search on treatment against the disease related with coronavirus (COVID-19). There are no current approved therapeutic options against the virus, although there is a rush for the development of drugs, vaccines and even the passive immunization through plasma from convalescent patients. This passive immunization is made with the administration of antibodies from patients that went through the infectious state of the disease and progress to clinical remission.
SARS-CoV-2, and its predecessor SARS-CoV-1, have great similarities between their genes and proteins; tis allow to hypothesize that the antibodies developed against SARS-CoV1 can recognize the antigens of SARS-CoV-2. In this manner, the transfusion of convalescent plasma to patients with the infection brings the probability on eliminating the infection, in this case SARS-CoV-2. There are evidence of this phenomenon observed in previous pandemics caused by SARS-CoV-1, Influenza AH1N1 and Ebola virus.
The objective of the study is to develop a therapeutic strategy based on the administration of plasma from patients with COVID-19 with clinical remission to patients that are coursing with the infection. The expected results hopes to establish an effective treatment and satisfactory recovery of patients with COVID-19. Also, we expect to describe the respective antibodies related against the SARS-CoV-2 infection.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
COVID-19 Pneumonia Convalescent Plasma | Biological: Convalescent plasma | Phase 1 Phase 2 |
The health contingency established against the Severe Acute Respiratory Syndrome associated type 2 Coronavirus (SARS-CoV-2) has promoted a race against the clock for the search on treatment against the disease related with coronavirus (COVID-19). There are no current approved therapeutic options against the virus, although there is a rush for the development of drugs, vaccines and even the passive immunization through plasma from convalescent patients. This passive immunization is made with the administration of antibodies from patients that went through the infectious state of the disease and progress to clinical remission.
SARS-CoV-2, and its predecessor SARS-CoV-1, have great similarities between their genes and proteins; tis allow to hypothesize that the antibodies developed against SARS-CoV1 can recognize the antigens of SARS-CoV-2. In this manner, the transfusion of convalescent plasma to patients with the infection brings the probability on eliminating the infection, in this case SARS-CoV-2. There are evidence of this phenomenon observed in previous pandemics caused by SARS-CoV-1, Influenza AH1N1 and Ebola virus.
The objective of the study is to develop a therapeutic strategy based on the administration of plasma from patients with COVID-19 with clinical remission to patients that are coursing with the infection. The expected results hopes to establish an effective treatment and satisfactory recovery of patients with COVID-19. Also, we expect to describe the respective antibodies related against the SARS-CoV-2 infection.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 15 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Intervention Model Description: | Pilot, experimental, randomized, prospective, longitudinal, clinical study |
Masking: | Double (Participant, Care Provider) |
Primary Purpose: | Treatment |
Official Title: | Pilot Clinical, Statistical and Epidemiological Study on Efficacy and Safety of Convalescent Plasma for the Management of Patients With COVID-19 |
Estimated Study Start Date : | July 6, 2020 |
Estimated Primary Completion Date : | March 1, 2021 |
Estimated Study Completion Date : | April 1, 2021 |

Arm | Intervention/treatment |
---|---|
Experimental: Convalescent plasma
Best available treatment + convalescent plasma Best available treatment: hemodynamic support, oxygen supplementation, antibiotic therapy (if required), and individualized treatment judged by the attending physician. Plasma will be split by aliquots of 200 ml for its storage on -60 celsius degrees until it's used. After defrosting, it will be administered on 2 200 ml separated doses on a 12 hours interval. |
Biological: Convalescent plasma
Best available treatment + convalescent plasma Best available treatment: hemodynamic support, oxygen supplementation, antibiotic therapy (if required), and individualized treatment judged by the attending physician. Plasma will be split by aliquots of 200 ml for its storage on -60 celsius degrees until it's used. After defrosting, it will be administered on 2 200 ml separated doses on a 12 hours interval. |
Placebo Comparator: Best available treatment
Best available treatment + Placebo (0.9% saline solution) Best available treatment: hemodynamic support, oxygen supplementation, antibiotic therapy (if required), and individualized treatment judged by the attending physician. Placebo will consist on 2 doses of 200 ml of 0.9% saline solution separated on a 12 hour interval. |
Biological: Convalescent plasma
Best available treatment + convalescent plasma Best available treatment: hemodynamic support, oxygen supplementation, antibiotic therapy (if required), and individualized treatment judged by the attending physician. Plasma will be split by aliquots of 200 ml for its storage on -60 celsius degrees until it's used. After defrosting, it will be administered on 2 200 ml separated doses on a 12 hours interval. |
- All-cause mortality [ Time Frame: 30 days ]Any cause mortality during the first 30 days of treatment
- Side effects [ Time Frame: 30 days ]Side effects associated with the administration of convalescent plasma
- Length of stay in Intensive Care Unit (ICU) [ Time Frame: 14 days ]Time to discharge from the ICU
- Length of stay in hospitalization [ Time Frame: 21 days ]Time for discharge from hospital
- Days of mechanical ventilation [ Time Frame: 14 days ]Number of days with ventilatory support
- Inflammatory biomarkers (d-dimer) [ Time Frame: 21 days ]change in D-dimer (micrograms/L)
- Inflammatory biomarkers (c-reactive protein) [ Time Frame: 21 days ]change in C-reactive protein (milligrams/dL)
- Inflammatory biomarkers (lactate dehydrogenase) [ Time Frame: 21 days ]Change in LDH (UI/L)
- Inflammatory biomarkers (ferritin) [ Time Frame: 21 days ]Change in ferritin (nanograms/mL)

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria (Donors):
- Signed informed consent
- At least positive for 1 q-PCR test for SARS-CoV-2
- 14 days of COVID-19 clinical remission
- Positive serologic test for SARS-CoV-2
- Requirements to donate according to NOM-253-SSA1-2012
- To accept sample storing for future study
Inclusion Criteria (Receptors):
- Signed informed consent provided by the patient, legal guardian or the health provider if not available
- Patients hospitalized in an ICU dedicated to the treatment of COVID-19 patients
- At least positive for 1 q-PCR test for SARS-CoV-2
- Patients with COVID-19 defined as severe or critically ill:
Severe: RF > 30 bpm, oxygen saturation <94%, Pa/FiO2 <301, bilateral lung infiltrates that extends in >50% (by chest radiograph or CT scan) in 24-48 hours Critically ill: Respiratory failure (PaO2 <60 mmHg or SatO2 <90% with FiO2 >60%) and septic shock (MAP <65 mmHg with vasoactive requirement, lactate > 2 mmol/L and SOFA score >1)
Exclusion Criteria:
- Positive pregnancy test
- Patients in lactation
- Informed consent not signed
- Patients involved in other treatment protocols
- Patients on immunomodulatory drugs (DMARDs, monoclonal antibodies or smal molecule drugs)

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04452812
Contact: Julio César Martínez Gallegos, MD, MMSc | 8113852249 | juliomartinez.18@hotmail.com |
Mexico | |
Hospital Universitario "Dr. Gonzalo Valdés Valdés" | |
Saltillo, Coahuila, Mexico, 25000 | |
Contact: Julio César Martínez Gallegos, MD, MSc 8113852249 juliomartinez.18@hotmail.com |
Responsible Party: | Universidad Autonoma de Coahuila |
ClinicalTrials.gov Identifier: | NCT04452812 |
Other Study ID Numbers: |
HUS-001/2020 |
First Posted: | June 30, 2020 Key Record Dates |
Last Update Posted: | July 7, 2020 |
Last Verified: | June 2020 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Supporting Materials: |
Study Protocol |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
COVID-19 Convalescent plasma plasmapheresis |
COVID-19 Respiratory Tract Infections Infections Pneumonia, Viral Pneumonia Virus Diseases |
Coronavirus Infections Coronaviridae Infections Nidovirales Infections RNA Virus Infections Lung Diseases Respiratory Tract Diseases |